Regulus Therapeutics Inc RGLS.OQ RGLS.O is expected to show no change in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Regulus Therapeutics Inc is for a loss of 24 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Regulus Therapeutics Inc is $9.00, above its last closing price of $7.85.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.21 | -0.20 | Beat | 4.8 | |
Sep. 30 2024 | -0.18 | -0.17 | -0.21 | Missed | -23.5 |
Jun. 30 2024 | -0.16 | -0.15 | -0.17 | Missed | -15.9 |
Mar. 31 2024 | -0.26 | -0.22 | -0.29 | Missed | -30.3 |
Dec. 31 2023 | -0.40 | -0.39 | -0.40 | Missed | -1.3 |
Sep. 30 2023 | -0.41 | -0.40 | -0.40 | Met | -0.8 |
Jun. 30 2023 | -0.41 | -0.41 | -0.37 | Beat | 9.8 |
Mar. 31 2023 | -0.44 | -0.44 | -0.42 | Beat | 3.8 |
This summary was machine generated May 5 at 20:04 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。